Heterozygous familial hypercholesterolemia (HeFH) is a hereditary disease characterized by significantly elevated levels of low-density lipoproteins (LDL) in the blood. This condition is the result of hereditary dysfunction of genes responsible for cholesterol metabolism, which leads to the accumulation of cholesterol in the body. It should be noted that HeFH leads to the early development of atherosclerosis and cardiovascular diseases, which is of significant clinical significance. Constant and average high levels of LDL cholesterol lead to the formation of atherosclerotic plaques, a high probability of heart attacks and strokes, which makes prevention and early diagnosis of the disease an integral part of medical practice.
History of the disease and interesting historical facts
Heterozygous familial hypercholesterolemia was first described in 1936 when two doctors working together in London noticed a link between high cholesterol and early cardiovascular events in members of the same family. Since then, many studies have been conducted that have revealed the genetic nature of the disease. In the 1980s, scientists identified genes involved in cholesterol metabolism, such as LDLR, the genes encoding the cholesterol receptors that are associated with most cases of HeFH. Interestingly, as knowledge about this condition in different populations has accumulated, clinical guidelines for its diagnosis and treatment have begun to be formulated.
Epidemiology
According to various studies, heterozygous familial hypercholesterolemia occurs with a frequency of approximately 1 in 200–500 people in the general population. Studies show that the frequency of this condition can vary significantly depending on ethnicity; for example, in some isolated populations (e.g., in the Jewish population), the frequency can reach 1 in 67 people. However, it is important to consider that many cases remain undiagnosed, which makes it difficult to accurately determine the prevalence of the disease. One of the large epidemiological studies in Europe showed that patients with HeFH have a two- to three-fold higher risk of cardiovascular complications compared to the general population.
Genetic predisposition to this disease
Heterozygous familial hypercholesterolemia is mainly caused by mutations in the genes responsible for the synthesis of lipoprotein receptors, in particular, in the LDLR gene (leptorin, encoding the LDL receptor). In addition, mutations in the APOB and PCSK9 genes can also lead to similar disorders. These genetic changes affect the body's ability to utilize LDL, which in turn leads to its accumulation in the blood plasma. Inheritance of the disease is autosomal dominant, which means that only one copy of the altered gene is enough to manifest clinical signs. This requires careful analysis of genetic predisposition, especially in family members with known cases of various forms of hypercholesterolemia.
Risk factors for the development of this disease
The main risk factors that contribute to the development of heterozygous familial hypercholesterolemia include:
- Heredity: family history of cardiovascular disease early in life.
- Comorbidities: Chronic metabolic disorders may worsen the condition of patients with HeFH.
- Lifestyle: low physical activity, poor diet high in saturated fats and trans fats.
- Smoking: negative impact on blood vessels and cholesterol levels.
- Exposure to stress factors: may increase inflammatory processes in the body.
It is important to note that even in the absence of clinical symptoms, risk factors can significantly increase the likelihood of developing cardiovascular disease in patients with HeFH.
Diagnosis of this disease
The main goal of diagnosing heterozygous familial hypercholesterolemia is early detection of the disease and assessment of the risk of cardiovascular complications. It includes the following set of measures:
- Clinical symptoms: Most often, elevated cholesterol levels and early development of atherosclerosis are detected.
- Laboratory tests: determination of the level of total cholesterol, LDL, HDL and triglycerides in the blood.
- Radiological examinations: Ultrasound diagnostics of carotid arteries to detect atherosclerotic plaques.
- Other types of diagnostics: genetic testing to confirm the presence of mutations in the relevant genes.
- Differential diagnosis: exclusion of other forms of hypercholesterolemia and conditions accompanied by increased cholesterol levels.
Correct diagnosis and interpretation of test results are key to initiating treatment and preventing complications.
Treatment
Treatment for heterozygous familial hypercholesterolemia is aimed at lowering LDL levels and preventing cardiovascular disease. It includes:
- General treatment: Lifestyle changes to lower cholesterol levels, including a diet low in saturated fat and regular physical activity.
- Pharmacological treatment: use of statins (eg, atorvastatin, simvastatin), which are the main drugs for lowering LDL. In some cases, additional groups of drugs are used, such as PCSK9 inhibitors (evolocumab, alirocumab).
- Surgical treatment: In severe forms of the disease, atherectomy or even liver transplantation may be indicated.
- Other types of treatment: laser therapy options, the use of herbal remedies, and educational support activities for patients.
Treatment is recommended to be carried out under the supervision of a physician with subsequent monitoring of the patient's health.
List of medications used to treat this disease
The main drugs used to treat heterozygous familial hypercholesterolemia include:
- Statins (atorvastatin, simvastatin, rosuvastatin).
- PCSK9 inhibitors (evolocumab, alirocumab).
- Fibrates (fenofibrate, gemfibrozil) have the ability to reduce triglyceride levels.
- Niacin - can be used to correct cholesterol levels.
- Omega-3 fatty acids - useful for improving lipid profile.
The effectiveness of each of these drugs must be assessed based on individual patient factors.
Disease monitoring
Monitoring of the condition of patients with heterozygous familial hypercholesterolemia includes:
- Control stages: regular measurement of cholesterol levels, assessment of the cardiovascular system and control of concomitant diseases.
- Forecast: With proper treatment and lifestyle, the prognosis for patients can be favorable, but early diagnosis is necessary to avoid complications.
- Complications: The most serious are myocardial infarction and strokes, which occur at a young age.
Patients should be under constant supervision of a cardiologist and other specialized specialists.
Age-related features of the disease
Heterozygous familial hypercholesterolemia may present at different stages of life. In children and adolescents, the disease is often detected only through screening tests, as clinical symptoms may be absent. Early diagnosis and intervention in children can significantly alter the risk of cardiovascular disease in adulthood. In adult women, cholesterol levels may be lower until menopause, after which the risk increases rapidly. In older people, especially those with underlying medical conditions, the risk of complications increases even more, making monitoring and treatment especially important.
Questions and Answers
- What is heterozygous familial hypercholesterolemia? It is an inherited disorder characterized by elevated LDL levels and a high risk of cardiovascular disease.
- What symptoms indicate the presence of the disease? The main symptoms are high levels of cholesterol in the blood and possible manifestations of atherosclerosis.
- How is the disease diagnosed? Diagnosis includes laboratory tests, genetic testing, and assessment of clinical symptoms.
- How is heterozygous familial hypercholesterolemia treated? Treatment includes lifestyle changes, medications, and in some cases surgery.
- What is the prognosis and control of the disease? If treatment is started in a timely manner and recommendations are followed, the prognosis may be favorable.
Advice from Dr. Oleg Korzhikov
In heterozygous familial hypercholesterolemia, it is important to pay attention to the following aspects:
— Try to monitor your cholesterol levels: regular medical examinations will help identify potential problems at an early stage.
— Proper nutrition and physical activity have a significant impact on cholesterol levels - try to balance your diet and devote time to sports.
— Remember to inform your doctor about any changes in your condition, especially if new symptoms arise. Regular communication with your doctor will ensure that you receive up-to-date advice and support.
— Get genetic testing if you have a family history of cardiovascular disease—it can help you better understand your risks.
